Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
Phase 2
900
about 6.3 years
18+
24 sites in AZ, CO, FL +7
About this study
Researchers are testing the safety and effectiveness of lunsekimig over a long period in adults with asthma. The trial will last up to 100 weeks, with treatment lasting up to 96 weeks. Participants who have previously completed other studies on this medication are eligible.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lunsekimig
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants having any treatmentemergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Secondary: Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores, Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activities for 12 years and older (AQLQ[S] +12) domain and total scores, Change from parent study baseline in pre bronchodilator (BD) FEV1, Change from parent study baseline in prebronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Respiratory